Targeting olfactomedin-like 3 inhibits tumor growth by impairing angiogenesis and pericyte coverage

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Antiangiogenic therapies targeting tumor endothelial cells or pericytes show limited efficacy as monotherapies.
• There is a need for dual-targeting strategies to improve anticancer treatment outcomes.
• Tumor microenvironment components play crucial roles in cancer progression.

Purpose of the Study:

• To identify novel proangiogenic factors in the tumor microenvironment.
• To investigate the role of Olfactomedin-like 3 (Olfml3) in tumor angiogenesis and growth.
• To evaluate the therapeutic potential of blocking Olfml3 for cancer treatment.

Main Methods:

• Identification of Olfml3 as a proangiogenic factor produced by tumor endothelial cells and pericytes.
• In vitro assays to assess Olfml3's effect on endothelial cell migration and sprouting.
• Administration of anti-Olfml3 antibodies in vivo to evaluate tumor vascularization, pericyte coverage, and tumor growth.
• Analysis of the SMAD1/5/8 signaling pathway activation by Olfml3 and BMP4.

Main Results:

• Olfactomedin-like 3 (Olfml3) is a novel proangiogenic cue secreted by tumor endothelial cells and pericytes.
• Blockade of Olfml3 using specific antibodies significantly reduced tumor vascularization, pericyte coverage, and tumor growth.
• In vitro, Olfml3 inhibition impaired endothelioma cell migration and sprouting.
• Olfml3 enhances the BMP4-induced SMAD1/5/8 signaling pathway, crucial for angiogenesis.

Conclusions:

• Olfactomedin-like 3 (Olfml3) blockade represents a promising dual-targeting strategy for cancer therapy.
• Targeting Olfml3 simultaneously affects endothelial cells and pericytes within the tumor microenvironment.
• This approach offers a novel therapeutic avenue to control tumor growth by inhibiting angiogenesis.